Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Referanser til livmorhalskreft

  1. Schiffman HM, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993 Jun 16;85(12):958-964.
  2. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6;348(6):518-527.
  3. Karlsen F, Kristensen GB, Holm R, Chitemere M, Hagmar B. High incidence of HPV in 146 cervical carcinomas. A study using three different pairs of consensus primers, also detecting viral genoms with putative deletions. Eur J Cancer 1995;31A:1511-1516.
  4. Nygard JF, Skare GB, Thoresen SO. The cervical cancer screening programme in <st1:country-region st1="http://unknownprefix/st1">Norway</st1:country-region> 1992-2000: changes in Pap smear coverage and incidence of cervical cancer. J Med Screen. 2002;9(2):86-91.
  5. Nygard JF, Nygard M, Skare GB, Thoresen SO. Screening histories og women with CIN 2/3 compared with women diagnosed with invasive cancer: a retrospective analysis of the Norwegian Coordinated Cervical Cancer screening Program. Cancer Causes Control 2005 May;16(4):463-474.
  6. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from randomized trial. The Atypical Squamous Cells of Undermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. J Natl Cancer Inst 2000;92(5):397-402.
  7. Worldwide burden of cancer attributable to HPV by site, country and HPV type. de Martel C, Plummer M, Vignat J, Franceschi S. Int J Cancer. 2017 Apr 1. doi: 10.1002/ijc.30716. [Epub ahead of print] PMID: 28369882.
  8. Bjørge T, Thoresen SO, Skare GB. Incidence, survival and mortality in cervical cancer in <st1:country-region st1="http://unknownprefix/st1">Norway </st1:country-region>1956-1990. Eur J Cancer 1993;29A(16):2291-2297.
  9. Gregg Van de Putte A, Lie K, Vach W, Baekeland M, Kristensen GB. Risk grouping in stage IB squamous cervical carcinoma. Gynecol Oncol 2005;99:106-112.
  10. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patiens with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1990;38(3):352-357.
  11. Kurman RJ, Carcangiu ML, Herrington CS and Young RH, editors. WHO Classification of Tumors of Female Reproductive Organs. Lyon: IARC Press; 2014. p 170-206.
  12. Alfsen GC, Kristensen GB, Skovlund E, Pettersen EO, Abeler VM. Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix: a population-based study of prognostic factors in 505 patients with nonsquamous cell carcinomas of the cervix. Cancer. 2001 Nov 1;92(9):2471-2483.
  13.  A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. Gynecol Oncol. 1999 May;73:177-83.
  14. Nasjonalt handlingsprogram med retningslinjer for gynekologisk kreft (2016). Helsedirektoratet.
  15. Cancer in Norway 2015, Cancer Registry of Norway, Institute of Population-based Research. Oslo, Norway.
  16. Plante, M. Evolution in Fertility-Preserving Options for Early-Stage Cervical Cancer. Radical Trachelectomy, Simple Trachelectomy, Neoadjuvant Chemotherapy. Int J Gynecol Cancer 2013;23: 982-989.
  17. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ.

    Gynecol Oncol. 1999 May;73:177-83.

Prosedyrer i Oncolex kan ikke erstatte faglig veiledning fra kvalifisert veileder. Den som følger prosedyrene har et selvstendig ansvar for at det foreligger nødvendig godkjenning, lisens eller autorisasjon.
Oslo universitetssykehus HF © 2017